Coherus Oncology (CHRS) Preferred Stock Liabilities (2013 - 2014)
Coherus Oncology (CHRS) posted Preferred Stock Liabilities of $161.2 million for Q3 2014, up 194.66% sequentially from $54.7 million in Q4 2013.
Coherus Oncology (CHRS) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Coherus Oncology has reported Preferred Stock Liabilities for 2 years, with the latest figure at $161.2 million in Q3 2014.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $161.2 million in Q3 2014, while the trailing twelve-month figure through Sep 2014 was $161.2 million (changed N/A YoY) and the FY2013 annual result came in at $54.7 million, up 993.9% from the prior year.
- Preferred Stock Liabilities climbed to $161.2 million in Q3 2014 per CHRS's latest filing, from $54.7 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $161.2 million in Q3 2014 and troughed at $54.7 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 161.16 Mn |
| Dec 31, 2013 | 54.70 Mn |